Linking estrogen receptor β expression with inflammatory bowel disease activity

Area of Science:

• Immunology
• Gastroenterology
• Endocrinology

Background:

• Inflammatory bowel disease (IBD), including Crohn disease (CD) and ulcerative colitis (UC), has poorly understood pathogenesis.
• Estrogens play a complex role in inflammation, with emerging evidence linking them to IBD development.

Purpose of the Study:

• To investigate the role of estrogen receptor beta (ERβ) in the pathogenesis of active CD and UC.
• To determine if ERβ expression levels correlate with disease activity and treatment response in IBD patients.

Main Methods:

• Quantified ERβ expression in peripheral blood T lymphocytes and colonic mucosa of CD/UC patients and healthy controls.
• Assessed ERβ expression in relation to disease activity (active vs. remission) and anti-TNF-α therapy response.
• Investigated the effect of interleukin-6 (IL-6) on ERβ expression in T lymphocytes and intestinal epithelial cells.

Main Results:

• Significantly reduced ERβ expression in T lymphocytes of active CD/UC patients compared to those in remission and healthy controls.
• Higher ERβ expression in T lymphocytes of anti-TNF-α responsive IBD patients versus non-responsive patients.
• Markedly decreased ERβ expression in colonic mucosa of active IBD patients, mirroring peripheral blood findings.
• Inverse correlation between ERβ expression and IL-6 serum levels; IL-6 exposure downregulated ERβ in vitro.

Conclusions:

• ERβ expression is altered in active IBD patients at both systemic and mucosal levels.
• IL-6 dysregulation contributes to ERβ downregulation in IBD.
• T cell-associated ERβ shows potential as a biomarker for endoscopic disease activity in IBD.